Veld Pharmaceuticals Partners with Chiesi to Launch Rare Disease Access Program Across Africa
Key Insights
Veld Pharmaceuticals GmbH (search) and Chiesi Farmaceutici S.p.A have announced a collaboration to expand patient access to nine rare-disease therapies through a Managed Access Program across Africa.
The program enables physicians to prescribe therapies to patients with serious unmet medical needs who meet defined medical eligibility criteria and have appropriate funding mechanisms in place.
Veld will administer the program and facilitate access to Chiesi's rare-disease therapies on a named-patient basis, ensuring full compliance with local regulatory, ethical, and pharmacovigilance requirements.
Veld Pharmaceuticals GmbH (search), a Switzerland-based pharmaceutical access and services company, has announced a collaboration with Chiesi Farmaceutici S.p.A to expand patient access to nine rare-disease therapies through a Managed Access Program (MAP) across Africa. The program is designed to enable physicians, where permitted by local regulations, to prescribe these therapies to patients with serious unmet medical needs who meet defined medical eligibility criteria and where appropriate funding mechanisms are in place.
Strategic Partnership for African Healthcare Access
"Veld is truly excited to partner with Chiesi to expand access to rare-disease therapies across Africa," said Patrick Jordan, Director, Veld Pharmaceuticals GmbH (search). "This collaboration reflects our shared commitment to ensuring that patients with the highest unmet needs are no longer defined by geography, while maintaining the highest standards of regulatory compliance, ethics, and patient safety."
The partnership addresses a critical gap in rare disease treatment access across the African continent, where patients often face significant barriers to obtaining specialized therapies due to regulatory, logistical, and economic challenges.
Program Structure and Implementation
Under the collaboration, Veld will administer the Managed Access Program and facilitate access to Chiesi's rare-disease therapies on a named-patient basis. The program will be conducted in full accordance with applicable local regulatory, ethical, and pharmacovigilance requirements, ensuring a compliant, patient-focused approach to medicine access.
"Ensuring timely access to innovative therapies for patients with rare diseases (search) remains a core priority for Chiesi," said Lawrence Isaacs, Head of Africa & Levant Region and Senior Director, Commercial Strategy, Haematology & Immunology, Rare Diseases EU & International, Chiesi Pharmaceuticals (search). "Through our collaboration with Veld, we are supporting responsible access pathways that align with local healthcare systems and regulatory frameworks across Africa."
Healthcare Professional Engagement
Physicians and healthcare professionals seeking information on patient eligibility and program details may contact medical@veldpharma.com. Patients and caregivers are advised to consult their treating physician for guidance on accessing these therapies through the program.
The collaboration represents a significant step toward addressing the geographic disparities in rare disease treatment access while maintaining rigorous safety and regulatory standards across diverse African healthcare systems.